Targeting CD38-dependent NAD
Human Metabolism
Immunology
Molecular Biology
Journal
iScience
ISSN: 2589-0042
Titre abrégé: iScience
Pays: United States
ID NLM: 101724038
Informations de publication
Date de publication:
22 Jan 2021
22 Jan 2021
Historique:
received:
12
05
2020
revised:
20
09
2020
accepted:
03
12
2020
entrez:
1
1
2021
pubmed:
2
1
2021
medline:
2
1
2021
Statut:
epublish
Résumé
The processes underlying synchronous multiple organ fibrosis in systemic sclerosis (SSc) remain poorly understood. Age-related pathologies are associated with organismal decline in nicotinamide adenine dinucleotide (NAD
Identifiants
pubmed: 33385109
doi: 10.1016/j.isci.2020.101902
pii: S2589-0042(20)31099-3
pmc: PMC7770554
doi:
Types de publication
Journal Article
Langues
eng
Pagination
101902Subventions
Organisme : NIA NIH HHS
ID : R56 AG054207
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG026094
Pays : United States
Organisme : NIAMS NIH HHS
ID : P30 AR075043
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG058812
Pays : United States
Organisme : NIAMS NIH HHS
ID : R21 AR074523
Pays : United States
Organisme : NIAMS NIH HHS
ID : K08 AR070285
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA233790
Pays : United States
Organisme : NIAMS NIH HHS
ID : R21 AR073371
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2020 The Authors.
Déclaration de conflit d'intérêts
J.V. reports being a consultant for TeneoBio and Mitobridge. C.C.S.C. reports holding a patent on the use of CD38 inhibitors for metabolic diseases that is licensed by Elysium Health. E.N.C reports being a consultant for TeneoBio, Calico, Mitobridge, and Cyokinetics. E.N.C is on the advisory board of Eolo pharmaceutical, Argentina. J.G.'s research was support by grants from Lilly, Almirall, AbbVie, Kyowa Kirin, and BMS/Celgene; and he reports serving on the Advisory Board of Lilly, BMS, Novartis, Kyowa Kirin, AnaptysBio, and Almirall.
Références
Arthritis Rheum. 2004 Dec;50(12):4008-21
pubmed: 15593186
Ann Rheum Dis. 2016 Jan;75(1):226-33
pubmed: 25180292
N Engl J Med. 2011 Jun 9;364(23):2235-44
pubmed: 21651395
Oncotarget. 2016 Oct 25;7(43):69321-69336
pubmed: 27732568
Biochem Biophys Res Commun. 2019 May 28;513(2):486-493
pubmed: 30975470
Cell Metab. 2016 Jun 14;23(6):1127-1139
pubmed: 27304511
Sci Transl Med. 2014 Apr 16;6(232):232ra50
pubmed: 24739758
J Pharmacol Exp Ther. 2019 Apr;369(1):55-64
pubmed: 30635470
Br J Pharmacol. 2016 Aug;173(15):2352-68
pubmed: 27174364
Cell Metab. 2016 Aug 9;24(2):269-82
pubmed: 27508874
J Invest Dermatol. 2004 Dec;123(6):1057-62
pubmed: 15610514
Proc Natl Acad Sci U S A. 1979 Aug;76(8):4061-5
pubmed: 315070
FASEB J. 2007 Nov;21(13):3629-39
pubmed: 17585054
Curr Opin Rheumatol. 2016 Nov;28(6):561-70
pubmed: 27533324
Am J Pathol. 2012 Apr;180(4):1340-55
pubmed: 22387320
Arthritis Rheumatol. 2020 Jul;72(7):1160-1169
pubmed: 32134204
Nat Rev Mol Cell Biol. 2016 Nov;17(11):679-690
pubmed: 27552971
Physiol Rev. 2008 Jul;88(3):841-86
pubmed: 18626062
Stem Cells Int. 2020 May 20;2020:3768718
pubmed: 32565826
Cell Metab. 2015 Jul 7;22(1):31-53
pubmed: 26118927
Blood. 1998 Aug 15;92(4):1324-33
pubmed: 9694721
J Clin Invest. 2007 Mar;117(3):557-67
pubmed: 17332883
Semin Cell Dev Biol. 2020 May;101:146-160
pubmed: 31859147
Am J Physiol Cell Physiol. 2018 Mar 1;314(3):C297-C309
pubmed: 29187364
Nat Rev Dis Primers. 2015 Apr 23;1:15002
pubmed: 27189141
Sci Signal. 2012 Sep 11;5(241):ra67
pubmed: 22969159
Int J Biochem Cell Biol. 1997 Oct;29(10):1149-66
pubmed: 9438379
Biochem Biophys Res Commun. 2006 Oct 13;349(1):353-9
pubmed: 16935261
Proc Natl Acad Sci U S A. 2015 Mar 3;112(9):2876-81
pubmed: 25730862
J Am Chem Soc. 2014 Apr 16;136(15):5656-63
pubmed: 24660829
Cell Metab. 2018 Jan 9;27(1):85-100.e8
pubmed: 29129787
FEBS Lett. 1998 Nov 20;439(3):291-6
pubmed: 9845340
Cell Metab. 2018 Mar 6;27(3):513-528
pubmed: 29249689
Nat Rev Rheumatol. 2011 Oct 25;8(1):42-54
pubmed: 22025123
JCI Insight. 2018 Jul 12;3(13):
pubmed: 29997297
Nat Rev Rheumatol. 2014 Jul;10(7):390-402
pubmed: 24752182
Trends Endocrinol Metab. 2017 May;28(5):340-353
pubmed: 28291578
Nat Rev Rheumatol. 2020 Jan;16(1):11-31
pubmed: 31792399
J Invest Dermatol. 2018 Apr;138(4):802-810
pubmed: 29080679
Front Immunol. 2019 May 31;10:1187
pubmed: 31214171
Rejuvenation Res. 2019 Apr;22(2):121-130
pubmed: 30124109
Nat Commun. 2016 Jun 03;7:11703
pubmed: 27256716
Nat Rev Drug Discov. 2020 Jan;19(1):57-75
pubmed: 31548636
PLoS One. 2015 Aug 19;10(8):e0134927
pubmed: 26287487
Nat Rev Rheumatol. 2019 Dec;15(12):705-730
pubmed: 31712723
PLoS One. 2011 Apr 26;6(4):e19194
pubmed: 21541336
J Mol Cell Cardiol. 2018 May;118:81-94
pubmed: 29476764
Curr Opin Rheumatol. 2020 Nov;32(6):488-496
pubmed: 32941246
J Invest Dermatol. 2013 May;133(5):1302-10
pubmed: 23303459
Proc Natl Acad Sci U S A. 2015 Sep 15;112(37):11648-53
pubmed: 26297248
Nat Metab. 2020 Nov;2(11):1284-1304
pubmed: 33199925
Biochim Biophys Acta Mol Basis Dis. 2019 Sep 1;1865(9):2451-2463
pubmed: 31195117
Arthritis Rheumatol. 2019 Oct;71(10):1701-1710
pubmed: 30920766
Trends Pharmacol Sci. 2018 Apr;39(4):424-436
pubmed: 29482842
Biol Pharm Bull. 2015;38(2):193-200
pubmed: 25747978
Biochem Biophys Res Commun. 2006 Jul 14;345(4):1386-92
pubmed: 16730329
F1000Res. 2018 Feb 1;7:132
pubmed: 29744033
FASEB J. 2002 Mar;16(3):302-14
pubmed: 11874980
Cell Metab. 2018 May 01;27(5):1081-1095.e10
pubmed: 29719225
Arthritis Rheumatol. 2015 May;67(5):1323-34
pubmed: 25707573
J Cell Physiol. 2007 Dec;213(3):663-71
pubmed: 17559085
Sci Transl Med. 2016 Oct 19;8(361):361ra139
pubmed: 27798264
Autoimmun Rev. 2018 Dec;17(12):1225-1234
pubmed: 30316997
Cell. 2013 Dec 19;155(7):1624-38
pubmed: 24360282
Arthritis Rheumatol. 2016 Aug;68(8):2003-15
pubmed: 26945694
Nature. 2019 May;569(7758):723-728
pubmed: 31043742
J Gerontol A Biol Sci Med Sci. 2017 May 1;72(5):595-602
pubmed: 27522058
Mol Cell Endocrinol. 2017 Nov 5;455:62-74
pubmed: 27825999
PLoS One. 2012;7(7):e42357
pubmed: 22848760